

Ticket #:

Request Date:

Request Time: _____

H.P. Acthar Gel[®] Prior Authorization Request Form (Page 1 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

| Member Information (required) | | | Provider Information (required) | | | |
|---|---|---|---|---------------------------------|----------------------|--|
| Member Name: | | | Provider Name: | | | |
| Insurance ID#: | | | NPI#: Spe | | Specialty: | |
| Date of Birth: | | | Office Phone: | | | |
| Street Address: | | | Office Fax: | | | |
| City: State: Zip: | | | Office Street Address: | | | |
| Phone: | I | I | City: | State: | Zip: | |
| | Ν | edication Info | rmation (required) | | | |
| Medication Name: | | | Strength: | | | |
| Check if requesting brand | | | Directions for Use: | | | |
| Check if request is for continuation of therapy | | | | | | |
| | | Clinical Inform | nation (required) | | | |
| Dermatologic diseas Edematous state: F Infantile spasms (W Multiple sclerosis Ophthalmic disease segment inflammatio Opsoclonus-myoclo Respiratory disease Rheumatic disorders Other diagnosis: | um sickness Systemic lupus eryther ses: Severe erythema r Proteinuria est Syndrome) s: Keratitis, iritis, iridocy on nus syndrome s: Sarcoidosis s: Psoriatic arthritis, rhe | nultiforme, Stevens-Joh yclitis, diffuse posterior u | atomyositis (polymyositis nsons syndrome uveitis and choroiditis, op le rheumatoid arthritis, a ICD-10 Code(s): | otic neuritis, unkylosing sp | | |
| Allergist Dermatologist Immunologist Nephrologist Neurologist Optometrist or opl Pulmonologist Rheumatologist | prescribed by or in cons | sultation with one of the | following specialists: | | | |
| Is H.P. Acthar being us | nistory of failure, contrai | ation of multiple scleros | is? DYes DNo to treatment with two co | orticosteroid | s (e.g., prednisone, | |

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

H.P. Acthar Gel[®] Prior Authorization Request Form (Page 2 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

| | d indications, answer the following: |
|--|--|
| randomized controlled tri | uested condition supported by two articles from major peer reviewed medical journals that present data from als supporting the proposed use or uses as generally safe and effective unless there is clear and convincing resent in a major peer-reviewed medical journal? D Yes D No |
| Does the patient have his | story of failure, contraindication, or intolerance to two corticosteroids (e.g., prednisone, methylprednisolone), t least two weeks? D Yes D No |
| For rheumatic disorder | s, also answer the following: |
| Select if the patient has of Psoriatic arthritis Rheumatoid arthritis Juvenile rheumatoid Ankylosing spondyl | one of the following diagnoses: s d arthritis (selected cases may require low-dose maintenance therapy) itis |
| Will H.P. Acthar be used exacerbation)? U Yes | as adjunctive therapy for short-term administration (to tide the patient over an acute episode or □ No |
| For collagen diseases, | also answer the following: |
| Select if the patient has o Systemic lupus ervt Systemic dermatom | |
| | during an exacerbation or as maintenance therapy? U Yes D No |
| | ses, also answer the following: |
| - | one of the following diagnoses: nultiforme |
| For allergic states, also | - |
| • | erum sickness? 🛛 Yes 🖸 No |
| - | e, also answer the following: |
| = | one of the following diagnoses: reitis or choroiditis |
| Will H.P. Acthar be used adnexa? 🛛 Yes 🖵 No | for severe acute and chronic allergic and inflammatory processes involving the eye and its |
| For respiratory disease | es, also answer the following: |
| Does the patient have sy | mptomatic sarcoidosis? 🛛 Yes 🖓 No |
| For edematous state, a | lso answer the following: |
| | one of the following diagnoses: rotic syndrome without uremia of the idiopathic type upus erythematosus |
| | to induce a diuresis or a remission? U Yes U No |

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: H.P.ActharGel Comm 5/2019

this review?

H.P. Acthar Gel[®] Prior Authorization Request Form (Page 3 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Authorized Medical Signature:

Telephone:

Date:

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

Please note: This request may be denied unless all required information is received.

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: H.P.ActharGel Comm 5/2019